聚苯乙烯磺酸钙防治慢性肾脏病(CKD)患者服用RAAS-Ⅰ致高钾血症的效果

Effect of Calcium Polystyrene Sulfonate in Prevention and Treatment of Hyperkalemia of Patients with Chronic Kidney Disease Induced by Taking RAAS-Ⅰ

目的探讨因服用肾素-血管紧张素-醛固酮系统抑制剂(RAAS-Ⅰ)致高钾血症的慢性肾脏病(CKD)患者应用聚苯乙烯磺酸钙进行防治的临床效果。方法选取惠州市第三人民医院诊治的CKD患者80例作为研究对象,所有患者均服用RAAS-Ⅰ 4周以上。将其随机分为观察组和对照组。对照组给予常规治疗,观察组给予聚苯乙烯磺酸钙联合治疗。统计观察组患者治疗前以及治疗2个月后24 h尿蛋白、血肌酐以及血钾变化,并对两组患者不同时段血钾水平进行统计分析。结果治疗后观察组24 h尿蛋白水平明显高于治疗前(P<0.05),血钾水平明显低于治疗前(P<0.05);观察组治疗1、3以及6个月时血钾水平均低于对照组(P<0.05)。结论聚苯乙烯磺酸钙治疗CKD患者服用RAAS-Ⅰ所致的高钾血症效果显著,血钾水平控制良好。

Objective To explore clinical effect of calcium polystyrene sulfonate in prevention and treatment of patients with hyperkalemia of chronic kidney disease （CKD） induced by taking RAAS - I. Methods 80 cases of patients with CKD treated in our hospital were selected as the study objects, and all the patients were treated with RAAS -1 for over 4 weeks, and were divided into observation group and control group randomly. The control group were given conventional treatment, and the observation group were combined with calcium polystyrene sulfonate. Changes of 24 h urine protein, serum creatinine and serum potassium levels before treatment and after treatment of 2 months were figured and observed in the observation group, and blood potassium level in different periods were figured and analyzed in the two groups. Results After treatment, 24 h urinary protein level in the observation group was significantly higher than that before treatment （P 〈 0. 05 ） , and serum potassium level was significantly lower than that before treatment （ P 〈 0. 05 ）. The levels of serum potassium at 1,3 , and 6 months of treatment in the observation group were lower than those in the control group （ P 〈 0. 05 ）. Conclusion The effect is obvious of calcium polystyrene sulfonate in prevention and treatment of patients with CKD induced by taking RAAS - 1, and blood potassium level is well controlled.